EU TPD3 Nicotine Pouch Cap: What 20mg/g Means for Sourcing

The European Commission is preparing its TPD3 legislative proposal, expected in the first half of 2026. Among its most consequential provisions: a proposed 20mg/g nicotine concentration cap for nicotine pouches. For manufacturers serving both US and EU markets, that single number creates a supply chain bifurcation that touches formulation, documentation, and ingredient sourcing decisions happening right now.

Here is the problem in concrete terms. The on! 8mg nicotine pouch, sold in the US in a mini format weighing approximately 0.3 grams, contains nicotine at a concentration of roughly 26.7 mg/g. That product, as currently formulated, would be illegal to sell in the EU under TPD3. The ZYN 6mg pouch at approximately 15 mg/g would pass. Same ingredient category, different format, different regulatory outcome. And the EU-wide cap is only part of the story, because national caps already in effect across member states range from 4 mg/g in Latvia to 16.6 mg/g in Finland.

If you manufacture nicotine pouches for international distribution, the era of one formulation for all markets is ending. What follows is a detailed breakdown of what TPD3 proposes, how national regulations compound the complexity, and what your ingredient supply chain needs to support.

What TPD3 Actually Proposes for Nicotine Pouches

TPD3 will formally bring nicotine pouches into EU regulatory scope for the first time. Under the current TPD2 framework, nicotine pouches exist in a regulatory gray area with no harmonized rules at the bloc level. Individual member states have filled that vacuum with a patchwork of national laws ranging from outright bans to permissive frameworks.

The proposed TPD3 provisions extend well beyond the nicotine cap:

• Nicotine concentration ceiling: 20mg/g of product weight, following the precedent set by TPD2's 20mg/ml cap for e-liquids
• Flavor restrictions: Likely limited to tobacco and menthol, mirroring existing restrictions in Denmark and Finland
• Ingredient disclosure: Mandatory reporting to the EU Common Entry Gate (EU-CEG) notification system
• Child-resistant packaging: Standardized requirements across all member states
• Health warnings: Harmonized labeling across the bloc
• Traceability: Product-level unique identifiers and supply chain tracking from manufacture to point of sale

The realistic implementation timeline extends further than many manufacturers assume. After the Commission tables its proposal in 2026, the ordinary legislative procedure requires Parliament review, Council negotiations, and trilogue. That process typically takes two to three years. Add the standard two-year transposition period for 27 member states, and the earliest realistic window for new TPD3 rules to take practical effect is 2028 to 2029. Manufacturers who begin reformulating and documenting now will have products ready when rules take effect. Those who wait will be scrambling while competitors are already shipping.

Why 20mg/g Is Not a Simple Pass-Fail Number

The 20mg/g cap measures nicotine concentration by product weight, not total nicotine per pouch. That distinction is critical because pouch format determines whether a product passes or fails.

Consider these US market products measured against the proposed cap:

Brand	mg/pouch	Pouch Weight	Concentration (mg/g)	TPD3 Status
ZYN	3 mg	~0.4 g	~7.5 mg/g	Compliant
ZYN	6 mg	~0.4 g	~15 mg/g	Compliant
ZYN	11 mg	~0.65 g	~17 mg/g	Compliant
on!	4 mg	~0.3 g	~13.3 mg/g	Compliant
on!	8 mg	~0.3 g	~26.7 mg/g	Non-compliant
VELO	11 mg	~0.7 g	~15.7 mg/g	Compliant
VELO	14 mg	~0.7 g	~20 mg/g	Borderline

The pattern is clear. Mini and slim format pouches, which use less filler material to deliver the same nicotine dose, produce higher mg/g concentrations. A product that is perfectly legal in the US can exceed the proposed EU cap not because it contains more nicotine, but because it uses a smaller pouch.

This creates a formulation lever that manufacturers must understand. To bring a high-strength mini pouch under the 20mg/g threshold, a manufacturer has two options: reduce total nicotine content (changing the consumer experience) or increase pouch weight with additional filler (changing the product format). Both options require adjusted nicotine dilution specifications from the ingredient supplier.

The National Patchwork: Where One Cap Is Not Enough

The proposed 20mg/g EU-wide cap will establish a ceiling, but multiple member states already enforce stricter national limits. Manufacturers targeting specific European markets need formulations that comply with the most restrictive applicable regulation.

Countries with Active Nicotine Caps

Country	Cap	Unit	Additional Restrictions
Denmark	9 mg	per pouch	Effective July 2025, full enforcement April 2026. Tobacco and menthol flavors only. Standardized packaging.
Czech Republic	10 mg	per pouch	Regulated sales permitted
Finland	16.6 mg	per gram (mg/g)	Mint and menthol flavors only
Latvia	4 mg	per gram (mg/g)	One of the strictest concentration caps in Europe
Spain (proposed)	0.99 mg	per pouch	Under EU TRIS notification. Six member states filed formal objections citing violation of free movement of goods under Article 34 TFEU.

Countries with Outright Bans

France banned nicotine pouch sales and possession effective April 1, 2026. Belgium banned sales in 2023, with updated enforcement rules from December 2025. The Netherlands banned retail sales effective January 1, 2025.

Countries with Permissive Frameworks

Sweden remains the most permissive market, with snus and pouches widely available and no concentration cap. Germany classifies nicotine pouches under food law rather than tobacco law, creating a fundamentally different regulatory framework from neighboring Austria, which integrated pouches into its tobacco monopoly system effective April 1, 2026.

The practical consequence: a manufacturer selling across European markets does not need one EU-compliant formulation. They potentially need multiple formulations optimized for different national thresholds. A pouch formulated at 19 mg/g to pass the EU-wide cap would still fail in Finland (16.6 mg/g ceiling), would need to deliver fewer than 9 mg total for Denmark, and would be entirely prohibited in France.

Taxation Adds Another Variable to Formulation Decisions

Weight-based taxation models in several member states create tension with concentration-based regulatory caps. Portugal introduced a EUR 0.065/g excise tax on nicotine pouches in 2026, calculated by net product weight and capped at products containing up to 12 mg per pouch. A weight-based tax incentivizes lighter pouches to minimize tax liability, but lighter pouches at the same nicotine level produce higher mg/g concentrations, pushing products closer to or beyond regulatory thresholds.

A manufacturer optimizing for Portuguese tax efficiency wants the lightest possible pouch. A manufacturer optimizing for TPD3 compliance wants enough pouch weight to keep concentration below 20 mg/g. These objectives conflict, and resolving that tension requires precise control over nicotine dilution specifications. The broader EU Tobacco Taxation Directive revision, tabled July 16, 2025, would bring novel nicotine products into the harmonized taxation scope, compounding formulation decisions with cost optimization.

What Dual-Market Supply Chains Actually Require

A manufacturer serving both US and EU markets faces a structural documentation challenge beyond reformulation. The two operate under fundamentally different regulatory philosophies.

US regulatory framework: No federal mg/g cap. FDA regulates by product authorization (PMTA), not concentration ceiling. The PMTA pathway requires extensive ingredient documentation including purity verification, HPHC characterization, and supply chain traceability. Higher-strength products are sold without specific FDA marketing orders. The market trends toward higher strengths and smaller formats.

EU regulatory framework (under TPD3): Concentration ceiling at 20 mg/g. National caps overlay the EU limit. Flavor restrictions to tobacco and menthol in multiple markets. Mandatory ingredient disclosure through EU-CEG. Extended traceability from manufacture to point of sale.

Supporting both markets from a single nicotine ingredient source requires several capabilities from your supplier:

Multiple concentration specifications. The same manufacturer may need USP/EP grade nicotine delivered at different dilution levels for different product lines. A US-market 8mg mini pouch and an EU-compliant version of the same brand require fundamentally different nicotine concentrations in the filler blend.

Dual pharmacopoeia documentation. USP and EP standards both require 99.5%+ purity, but testing protocols and documentation formats differ. A supplier maintaining dual certification eliminates the need to re-qualify when adjusting formulations between markets.

Batch-level traceability. EU traceability requirements under TPD3 demand full chain-of-custody documentation from raw nicotine through finished product. US FDA PMTA compliance requires separate documentation tracks. Both must trace back to the same underlying ingredient batches.

Flexible dilution without re-qualification. The core value is a supplier who can adjust concentration specifications without forcing a full re-qualification. This requires consistent base nicotine quality across batches, documented dilution protocols, and stability data at multiple concentration levels. Certificates of Analysis must map to both USP and EP monographs.

Format optimization support. Because the 20mg/g cap is a concentration metric, pouch weight is a formulation lever. A supplier who understands how nicotine salt selection, dilution ratio, and pouch weight interact can help manufacturers stay compliant without sacrificing consumer experience or starting reformulation from scratch.

The Traceability Requirement That Changes Supplier Selection

TPD3 extends track-and-trace requirements to nicotine pouches, requiring product-level unique identifiers for every SKU, supply chain tracking from manufacturing to point of sale, EU-CEG notification integration, and standardized ingredient reporting. For ingredient suppliers, this means lot-level tracking and documentation must be audit-ready before your customer's finished product enters the EU supply chain. A supplier already operating under GMP practices with full batch documentation and CoA transparency has a structural advantage over one that needs to build that infrastructure from scratch.

The state-level regulatory fragmentation in the US is already pushing manufacturers toward suppliers with stronger documentation programs. TPD3 traceability will accelerate that trend in Europe.

Planning Horizon: What to Do Before 2028

TPD3 implementation is realistically two to three years away. That window is not as generous as it sounds when you factor in product development cycles, stability testing, and regulatory submissions. Here is a practical timeline for ingredient buyers:

Now through Q4 2026: Audit your product portfolio against the 20mg/g cap and the strictest national cap in each target market. Identify which SKUs need reformulation. Begin conversations with your ingredient supplier about adjusted dilution specifications and dual-market documentation.

2027: Complete reformulation and stability testing for EU-compliant product lines. Ensure your supplier can provide CoAs mapping to EP monographs alongside existing USP documentation. Build out traceability documentation chains that satisfy anticipated TPD3 requirements.

2028 and beyond: Products and documentation should be submission-ready when transposition deadlines arrive. Manufacturers with everything in place will have first-mover advantage in newly regulated markets.

The manufacturers who will navigate this transition smoothly are those whose ingredient suppliers can support multiple concentration specs from a single qualified source, with documentation satisfying both US and EU frameworks. That capability starts with an ingredient partner that already has the quality infrastructure, pharmacopoeia certifications, and documentation discipline for dual-market supply chains.

NicAlliance provides USP/EP grade nicotine with flexible dilution specifications and full batch documentation supporting both US and EU regulatory requirements. If you are planning for TPD3 compliance, request a sample with dual-market CoA documentation to evaluate fit.

Frequently Asked Questions